1. Home
  2. AIFC vs SCYX Comparison

AIFC vs SCYX Comparison

Compare AIFC & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AI Financial Corporation Common Stock

AIFC

AI Financial Corporation Common Stock

N/A

Current Price

$0.61

Market Cap

59.0M

Sector

Finance

ML Signal

N/A

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$5.25

Market Cap

51.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIFC
SCYX
Founded
N/A
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
59.0M
51.1M
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
AIFC
SCYX
Price
$0.61
$5.25
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
870.4K
247.1K
Earning Date
N/A
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
$12,532,000.00
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$0.57
52 Week High
$0.70
$5.62

Technical Indicators

Market Signals
Indicator
AIFC
SCYX
Relative Strength Index (RSI) 69.07 61.44
Support Level $0.52 $4.65
Resistance Level $0.63 $5.58
Average True Range (ATR) 0.05 0.38
MACD 0.02 -0.00
Stochastic Oscillator 90.46 69.03

Price Performance

Historical Comparison
AIFC
SCYX

About AIFC AI Financial Corporation Common Stock

AI Financial Corp is a payment infrastructure company. The company provides payment infrastructure services focused on payment processing and financial transaction technologies. Its capabilities include payment processing, security features, tokenization, and AI-based commerce solutions. It also provides infrastructure for crypto and decentralized finance (DeFi) payment processing and is developing additional capabilities for automated and programmable payment systems.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: